In an effort to foster progress in cancer research, the National Institute of Standards and Technology (NIST) is releasing detailed and comprehensive data about the entire genetic content of a ...

Cancer does not develop overnight. It can take decades for cancer‐promoting changes in the genome to eventually lead to the ...

In an effort to foster progress in cancer research, the National Institute of Standards and Technology (NIST) is releasing ...

The rapid advancement of single-cell and single-nucleus RNA sequencing (sc/snRNA-seq) has opened unprecedented windows into ...

A new AI tool, AAnet, has discovered five distinct cell types within tumors, offering a deeper look into cancer's inner diversity. This insight could transform how we treat cancer, enabling ...

Neurons often receive organelles called mitochondria from other cells. It emerges that neurons donate mitochondria that support cancer-cell spread.

On June 24, Nuvalent announced positive pivotal data from its global ARROS-1 Phase 1/2 clinical trial for zidesamtinib.

On June 1, Arcus Biosciences presented the first data for casdatifan plus cabozantinib in oral metastatic kidney cancer, which showed a confirmed response.

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.

To evaluate the efficacy of patritumab deruxtecan (HER3-DXd) in patients with advanced non–small cell lung cancer without common EGFR -activating mutations. Knowledge Generated HER3-DXd therapy ...